Background: Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic. To date, the clinical characteristics of COVID-19-infected cancer patients remain largely unknown.
Patients and methods: In this retrospective cohort study, we included cancer patients with laboratory-confirmed COVID-19 from three designated hospitals in Wuhan, China. Clinical data were collected from medical records from 13 January 2020 to 26 February 2020. Univariate and multivariate analyses were carried out to assess the risk factors associated with severe events defined as a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death.
Results: A total of 28 COVID-19-infected cancer patients were included; 17 (60.7%) patients were male. Median (interquartile range) age was 65.0 (56.0-70.0) years. Lung cancer was the most frequent cancer type (n = 7; 25.0%). Eight (28.6%) patients were suspected to have hospital-associated transmission. The following clinical features were shown in our cohort: fever (n = 23, 82.1%), dry cough (n = 22, 81%), and dyspnoea (n = 14, 50.0%), along with lymphopaenia (n = 23, 82.1%), high level of high-sensitivity C-reactive protein (n = 23, 82.1%), anaemia (n = 21, 75.0%), and hypoproteinaemia (n = 25, 89.3%). The common chest computed tomography (CT) findings were ground-glass opacity (n = 21, 75.0%) and patchy consolidation (n = 13, 46.3%). A total of 15 (53.6%) patients had severe events and the mortality rate was 28.6%. If the last antitumour treatment was within 14 days, it significantly increased the risk of developing severe events [hazard ratio (HR) = 4.079, 95% confidence interval (CI) 1.086-15.322, P = 0.037]. Furthermore, patchy consolidation on CT on admission was associated with a higher risk of developing severe events (HR = 5.438, 95% CI 1.498-19.748, P = 0.010).
Conclusions: Cancer patients show deteriorating conditions and poor outcomes from the COVID-19 infection. It is recommended that cancer patients receiving antitumour treatments should have vigorous screening for COVID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 coinfection.
Keywords: COVID-19; cancer; retrospective case study; severe clinical events.
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Disclosure All authors have declared no conflicts of interest.
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.JAMA Cardiol. 2020 Mar 25:e200950. doi: 10.1001/jamacardio.2020.0950. Online ahead of print. JAMA Cardiol. 2020. PMID: 32211816 Free PMC article.
Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients.Theranostics. 2020 Apr 27;10(12):5641-5648. doi: 10.7150/thno.46465. eCollection 2020. Theranostics. 2020. PMID: 32373237 Free PMC article. Clinical Trial.
Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.Int J Clin Pharm. 2020 May 14:1-9. doi: 10.1007/s11096-020-01031-2. Online ahead of print. Int J Clin Pharm. 2020. PMID: 32410206 Free PMC article.
Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.J Clin Pharm Ther. 2020 May 25. doi: 10.1111/jcpt.13170. Online ahead of print. J Clin Pharm Ther. 2020. PMID: 32449224 Review.
Diagnostic value and key features of computed tomography in Coronavirus Disease 2019.Emerg Microbes Infect. 2020 Dec;9(1):787-793. doi: 10.1080/22221751.2020.1750307. Emerg Microbes Infect. 2020. PMID: 32241244 Free PMC article. Review.
Cited by 16 articles
The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population.Curr Oncol Rep. 2020 May 28;22(6):60. doi: 10.1007/s11912-020-00945-4. Curr Oncol Rep. 2020. PMID: 32462289 Free PMC article. Review.
Impact of the COVID-19 Outbreak on the Management of Patients with Cancer.Target Oncol. 2020 May 22:1-11. doi: 10.1007/s11523-020-00721-1. Online ahead of print. Target Oncol. 2020. PMID: 32445083 Free PMC article. Review.
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer.ESMO Open. 2020 May;5(Suppl 3):e000804. doi: 10.1136/esmoopen-2020-000804. ESMO Open. 2020. PMID: 32423899 Free PMC article. Review.
Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients.Version 2. J Orthop Surg Res. 2020 May 18;15(1):178. doi: 10.1186/s13018-020-01702-w. J Orthop Surg Res. 2020. PMID: 32423471 Free PMC article. No abstract available.
How we treat patients with brain tumour during the COVID-19 pandemic.ESMO Open. 2020 May;4(Suppl 2):e000789. doi: 10.1136/esmoopen-2020-000789. ESMO Open. 2020. PMID: 32409298 Free PMC article. Review.